文献速递临床试验与 GCP

辛伐他汀联合利福昔明治疗失代偿期肝硬化:一项随机临床试验

Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

这项双盲、安慰剂对照、3期试验在14家欧洲医院纳入237例失代偿期肝硬化患者,随机接受辛伐他汀20 mg/d联合利福昔明1200 mg/d或安慰剂治疗12个月。结果显示,在标准治疗基础上加用辛伐他汀联合利福昔明并未改善慢加急性肝衰竭发生率、移植或死亡、肝硬化并发症等结局,治疗组有3例(2.6%)发生横纹肌溶解。

要点

  • 辛伐他汀联合利福昔明组与安慰剂组的慢加急性肝衰竭发生率无显著差异(17.9% vs 14.2%)。
  • 移植或死亡(18.8% vs 24.2%)及肝硬化并发症复合终点(42.7% vs 45.8%)两组间均无显著差异。
  • 治疗组有3例(2.6%)发生横纹肌溶解,不良事件发生率两组相似。

核心结论

  • 在标准治疗基础上加用辛伐他汀联合利福昔明并未改善失代偿期肝硬化患者的结局。

研究设计与样本

  • 双盲、安慰剂对照、3期试验,于2019年1月至2022年12月在14家欧洲医院开展,末次随访时间为2022年12月。
  • 共随机237例失代偿期肝硬化患者,其中Child-Pugh B级194例、C级43例;72%为男性,平均年龄57岁。
  • 患者随机接受辛伐他汀20 mg/d联合利福昔明1200 mg/d(n=117)或外观相同的安慰剂(n=120),在标准治疗基础上治疗12个月,按Child-Pugh B或C级分层。

主要发现

  • 慢加急性肝衰竭发生率:治疗组21例(17.9%)vs 安慰剂组17例(14.2%),HR 1.23(95%CI 0.65-2.34),P=0.52。
  • 移植或死亡:治疗组22例(18.8%)vs 安慰剂组29例(24.2%),HR 0.75(95%CI 0.43-1.32),P=0.32。
  • 肝硬化并发症复合终点:治疗组50例(42.7%)vs 安慰剂组55例(45.8%),HR 0.93(95%CI 0.63-1.36),P=0.70。
  • 不良事件发生率两组相似(426 vs 419,P=0.59),但治疗组有3例(2.6%)发生横纹肌溶解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are no useful treatments to prevent the development of severe complications of liver cirrhosis. Simvastatin and rifaximin have shown beneficial effects in liver cirrhosis. OBJECTIVE: To assess whether simvastatin combined with rifaximin improves outcomes in patients with decompensated cirrhosis. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled, phase 3 trial conducted among patients with decompensated cirrhosis in 14 European hospitals between January 2019 and December 2022. The last date of follow-up was December 2022. INTERVENTIONS: Patients were randomly assigned to receive simvastatin, 20 mg/d, plus rifaximin, 1200 mg/d (n = 117), or identical-appearing placebo (n = 120) for 12 months in addition to standard therapy, stratified according to Child-Pugh class B or C. MAIN OUTCOMES AND MEASURES: The primary end point was incidence of severe complications of liver cirrhosis associated with organ failure meeting criteria for acute-on-chronic liver failure. Secondary outcomes included transplant or death and a composite end point of complications of cirrhosis (ascites, hepatic encephalopathy, variceal bleeding, acute kidney injury, and infection). RESULTS: Among the 237 participants randomized (Child-Pugh class B: n = 194; Child-Pugh class C: n = 43), 72% were male and the mean age was 57 years. There were no differences between the 2 groups in terms of development of acute-on-chronic liver failure (21 [17.9%] vs 17 [14.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 1.23; 95% CI, 0.65-2.34; P = .52); transplant or death (22 [18.8%] vs 29 [24.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.75; 95% CI, 0.43-1.32; P = .32); or development of complications of cirrhosis (50 [42.7%] vs 55 [45.8%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.93; 95% CI, 0.63-1.36; P = .70). Incidence of adverse events was similar in both groups (426 vs 419; P = .59), but 3 patients in the treatment group (2.6%) developed rhabdomyolysis. CONCLUSIONS AND RELEVANCE: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03780673.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Pose E, Jiménez C, Zaccherini G, et al. Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial. JAMA. 2025. PMID: 39908052. doi:10.1001/jama.2024.27441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。